Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Fineline Cube Aug 19, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Fineline Cube Aug 19, 2026
Company Deals

Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...

Company

Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development

Fineline Cube Sep 21, 2022

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...

Policy / Regulatory

Beijing Designates 923 Medical Entities for National Reimbursement Drug List

Fineline Cube Sep 21, 2022

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...

Company

Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift

Fineline Cube Sep 20, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...

Company Drug

Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China

Fineline Cube Sep 20, 2022

China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...

Company Drug

Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study

Fineline Cube Sep 20, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...

Company Deals

WuXi Biologics Partners with Elpiscience for Macromolecule Development

Fineline Cube Sep 20, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...

Company Drug

Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study

Fineline Cube Sep 20, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...

Company Drug

Clover Biopharmaceuticals Reports Positive Phase III Data for COVID-19 Vaccine SCB-2019

Fineline Cube Sep 20, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...

Company Drug

RemeGen Announces Positive Phase III Results for Telitacicept in SLE

Fineline Cube Sep 20, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...

Company Drug

BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor

Fineline Cube Sep 20, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia

Fineline Cube Sep 20, 2022

Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...

Company Deals Hospital

Beijing Launches HIV Precision Medicine Standardization Project

Fineline Cube Sep 20, 2022

On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...

Company Deals

Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar

Fineline Cube Sep 20, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive...

Company Deals

Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline

Fineline Cube Sep 20, 2022

China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi...

Company Medical Device

Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

Lepu Medtech Prices GDR Offering for International Expansion

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced...

Company Deals

Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D

Fineline Cube Sep 19, 2022

China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money...

Policy / Regulatory

NHSA Launches Expert Review for 2025 NRDL Update in China

Fineline Cube Sep 19, 2022

The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...

Company Drug

Daehwa Pharmaceutical Files NDA for Liporaxel in China for Gastric Cancer Treatment

Fineline Cube Sep 19, 2022

South Korea’s Daehwa Pharmaceutical (KOSDAQ: 067080) has announced the filing of a New Drug Application...

Posts pagination

1 … 667 668 669 … 710

Recent updates

  • Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China
  • Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists
  • FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19
  • Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting
  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Company Medical Device

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.